Sign in to view Jeniece’s full profile
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Jeniece’s full profile
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Detroit Metropolitan Area
Sign in to view Jeniece’s full profile
Jeniece can introduce you to 10+ people at Agenus
Join with email
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
6K followers
500+ connections
Sign in to view Jeniece’s full profile
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Jeniece
Jeniece can introduce you to 10+ people at Agenus
Join with email
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Jeniece
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Jeniece’s full profile
or
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Activity
6K followers
-
Jeniece Waite reposted thisJeniece Waite reposted thisAgenus announces new data at the #AACR2026 Annual Meeting, from an investigator-initiated Phase II study evaluating botensilimab + balstilimab (#BOT/BAL) in combination with MiNK Therapeutics agenT-797 #iNKT cell therapy in PD-1 refractory gastroesophageal (GEC) cancer. 🔹 April 20, 2026 🔹 2:00–5:00 PM PT / 5:00–8:00 PM ET 🔹 Poster Section 52 | Abstract CT166 #AACR26 #Immunotherapy #Oncology #CancerResearch
-
Jeniece Waite reposted thisJeniece Waite reposted thisA significant milestone for Agenus and the #BOT+BAL program. The first patient has enrolled in our global Phase 3 #BATTMAN (CO.33) trial evaluating botensilimab + balstilimab in refractory MSS/pMMR metastatic colorectal cancer — a population that has historically not benefited from immunotherapy. This registrational study spans more than 100 sites across Canada, France, Australia, and New Zealand, reflecting the urgency to bring new options to patients. 🔗 Read the full announcement: https://bit.ly/3KSL3Qw #Oncology #Immunotherapy #ColorectalCancer #ClinicalTrials #Biotech
-
Jeniece Waite reposted thisJeniece Waite reposted thisMarch brings attention to colorectal cancer. But for patients and families, the urgency doesn’t follow a calendar. #CRC continues to rise, especially among younger adults, and is the leading cause of cancer-related death in people under 50 in the U.S. At Agenus, our focus remains clear: advancing innovation for patients who have historically had the fewest options, and working to ensure access keeps pace with science. The work continues. #CRCAwarenessMonth #Innovation #Immunotherapy
-
Jeniece Waite reposted thisJeniece Waite reposted thisFor many patients, survival comes with lasting side effects from conventional treatments like neuropathy, bowel dysfunction, fertility loss. Extending life matters. Preserving quality of living matters just as much. The future must aim higher than incremental gains. #CRCAwarenessMonth #QualityLiving #CRC #Immunotherapy
-
Jeniece Waite reposted thisJeniece Waite reposted thisApproximately 95% of metastatic colorectal cancer (mCRC) is microsatellite stable (MSS). These tumors have historically been resistant to immunotherapy. For decades, treatment has relied heavily on chemotherapy, radiation, and surgery—often with long-term impacts to quality-of-living. Patients deserve innovation that reaches the majority. #CRCAwarenessMonth #MSS #CRC #Immunotherapy
-
Jeniece Waite reposted thisJeniece Waite reposted this💥An excellent day for a scientist often includes making a truly novel discovery, which stands out as a significant achievement. Witnessing a student successfully defend their thesis and being awarded their doctorate is another highlight. These moments reflect personal accomplishments and contribute to the advancement of knowledge and the growth of future scientists. Yesterday, I experienced another memorable moment that made it an excellent day. I presented a 50-minute lecture in a conference room at Agenus , filled with physicians and scientists, where I presented the efforts of my colleagues and me to develop more effective cancer immunotherapy. I covered preclinical and clinical work from the Earle A. Chiles Research Institute / Providence Cancer Institute & UbiVac , focusing on our strategies and #DarkGenome-derived non-canonical #DarkMatter #Cancer #Antigens. The engaging questions and dialogue from attendees, including the Chairman & CEO, Garo Armen, extended the lecture/discussion to about two hours. 💥TWO HOURS OF DISCUSSION WITH EXUCATED AND ENGAGED EXPERTS IS THRILLING! Thank you Dhan Chand & Steven O'Day for the invite.. As an added plus I met Sandra Craig, the person who oversaw the production of #Antigenics (the biotech that morphed into Agenus) personalized #Cancer vaccines for the renal and melanoma trials that I believe started in the last century. Axel Hoos
-
Jeniece Waite reposted thisJeniece Waite reposted thisAgenus will present a poster at the AACR Immuno-Oncology Conference (#AACR-IO) 2026, highlighting biomarker analyses from the investigational BOT+BAL immunotherapy program. 📍 Los Angeles 📅 Poster presentation: Thursday, February 19 🗓 Time: 12:15-3:15PM PT / 3:15-6:15 PM ET The accepted abstract focuses on systemic and tumor-microenvironment inflammation in patients with immunologically “cold,” treatment-refractory cancers treated with botensilimab alone or in combination with balstilimab. 🔗 Read the full press release: https://bit.ly/3KSL3Qw #AACRIO #ImmunoOncology #CancerResearch #Biomarkers #BOTBAL
-
Jeniece Waite reposted thisJeniece Waite reposted thisToday, Agenus announced the closing of our $141M strategic collaboration with Zydus Group; a defining milestone as we advance #botensilimab + balstilimab (#BOT+BAL) toward global impact. This collaboration strengthens our balance sheet and secures committed U.S. biologics manufacturing capacity at a pivotal moment, enabling disciplined Phase 3 execution, expanded authorized paid patient access, and long-term commercial readiness. With these foundations in place, Agenus enters 2026 focused on execution: advancing BOT+BAL through late-stage development and progressing toward regulatory submission supported by one of the most substantial clinical datasets generated in MSS colorectal cancer. Read the release: https://bit.ly/3KSL3Qw #Innovation #biotech #CRC #BATTMAN #Immunotherapy
-
Jeniece Waite reposted thisJeniece Waite reposted thisAccess matters—especially when standard options have been exhausted. France has expanded national compassionate access to #BOT+BAL, enabling fully reimbursed, hospital-based access across three hard-to-treat solid tumors under a single, nationally standardized AAC protocol. This update extends access beyond colorectal cancer to include platinum-resistant ovarian cancer and advanced soft-tissue sarcomas—diseases with substantial unmet medical need and historically limited responsiveness to immunotherapy. We are encouraged by France’s continued leadership in enabling responsible early access while maintaining rigorous oversight and real-world evidence collection. For patients, clinicians, and families navigating limited options, this expansion represents another meaningful step forward. Read Release: https://bit.ly/3KSL3Qw #PatientAccess #Immunotherapy #Oncology #OvarianCancer #Sarcoma #ColorectalCancer #AAC #GlobalHealth
-
Jeniece Waite liked thisJeniece Waite liked thisNew data from MiNK Therapeutics will be presented at the American Society of Gene and Cell Therapy (#ASGCT26) Annual Meeting, highlighting the context-dependent activity of invariant natural killer T (iNKT) cells. Additional presentation details will be shared as the conference program becomes available. Read the release: https://bit.ly/47tm7bb #iNKT #CellTherapy #Immunotherapy #ARDS
-
Jeniece Waite liked thisJeniece Waite liked thisAgenus announces new data at the #AACR2026 Annual Meeting, from an investigator-initiated Phase II study evaluating botensilimab + balstilimab (#BOT/BAL) in combination with MiNK Therapeutics agenT-797 #iNKT cell therapy in PD-1 refractory gastroesophageal (GEC) cancer. 🔹 April 20, 2026 🔹 2:00–5:00 PM PT / 5:00–8:00 PM ET 🔹 Poster Section 52 | Abstract CT166 #AACR26 #Immunotherapy #Oncology #CancerResearch
-
Jeniece Waite liked thisSo proud of my Mom and all her accomplishments in healthcare! I strive to be more like her every day in my own career. 🎉Jeniece Waite liked thisHonored to represent GI Partners of Illinois this weekend at the Specialty Networks, a Cardinal Health company Gastroenterology Conference in Orlando. It was truly an impressive turnout — a reflection of the continued momentum and innovation happening across our field. Events like this serve as a powerful reminder that the future of gastroenterology is being actively shaped by collaboration, data, and forward-thinking leadership. Grateful for the opportunity to connect with so many trailblazers doing incredible work, including Deborah McNeilance COO MBA Katherine Fetscher, Mallika Khandelwal among many others who are pushing the boundaries of what’s possible in GI care. A special shoutout to Melanie Berg MS, RD, LDN and Virginia Bove for organizing such an outstanding event. The energy, collaboration, and thought leadership throughout the conference were a direct reflection of your efforts and the impact you both continue to have within the GI community is truly profound. Excited to bring back new insights, partnerships, and ideas as we continue to advance patient care and innovation at GI Partners of Illinois. #Gastroenterology #HealthcareLeadership #Innovation #Networking #GIPartnersofIllinois #SpecialtyNetworks #HealthcareInnovation
-
Jeniece Waite liked thisJeniece Waite liked thisAgenus has enrolled the first patient in its global Phase 3 BATTMAN trial evaluating botensilimab + balstilimab in refractory MSS/pMMR metastatic colorectal cancer https://lnkd.in/e-AZG49u Garo Armen Jennifer S. Buell Steven O'Day Robin Taylor Tracy Clemente Craig Winter Zack Armen #Agenus #OncoDailyBiotech #Biotech #ClinicalTrials #ColorectalCancer #ImmunotherapyAgenus Enrolls First Patient in Phase 3 BATTMAN Trial for MSS/pMMR Metastatic Colorectal Cancer - OncoDailyAgenus Enrolls First Patient in Phase 3 BATTMAN Trial for MSS/pMMR Metastatic Colorectal Cancer - OncoDaily
-
Jeniece Waite liked thisJeniece Waite liked thisLast week I made the decision to leave my role as an Account Executive at Weaviate, and I'm planning to take the next six months as an intentional career break. The people at Weaviate are the real deal. They're sharp, passionate, and doing work that is actually moving the AI search space forward. I'm so grateful for my time there, and rooting hard for them. I'm using this time well: → Investing in my technical depth. Thirteen years of enterprise sales has given me strong instincts, but I want to understand the technology at a deeper level. Getting hands-on with AI infrastructure, building projects, and earning credentials. Coming back as the AE who can go toe-to-toe with an engineering team. → Soaking up a Seattle summer with my daughter. Anyone who lives here knows you don't waste a Pacific Northwest summer, so I don't plan to. → Traveling and actually disconnecting for a bit. Send me where you've been lately and why you loved it! This felt like the right moment to pause, invest in myself, and be thoughtful about what comes next rather than just jumping to the next thing. I'll be around and always happy to connect, especially if you're working on something in the AI or data infrastructure space. Reach out! #CareerBreak #TechSales #AI #VectorSearch
-
Jeniece Waite liked thisJeniece Waite liked thisMiNK Therapeutics announced abstract acceptance for presentation at the American Thoracic Society (ATS) International Conference 2026, highlighting a novel combination approach with #agenT-797 in persistent infection. 📍 Poster #103 | May 20, 2026 | 11:00 AM-1:00PM EDT Read the full announcement: https://bit.ly/47tm7bb #ATS2026 #Immunotherapy #CellTherapy #PulmonaryMedicine #Biotech
-
Jeniece Waite liked thisJeniece Waite liked thisAfter four fantastic years at Life Sciences Recruitment, I’ve decided to move on and build something new. I want to thank my business partners, Greg Bell and Donna Duley ACA BA Econ and the whole Morgan Prestwich - Life Science & Healthcare Executive Search family, for their support and the success we shared over the last 10 years! I wish them every success moving forward. I’m excited to launch The Budd Group, an independent venture where I’ll be personally working directly with clients to deliver a more flexible, hands-on approach to hiring. I’ll be supporting biotech, diagnostics and CDMOs with both targeted search and embedded talent acquisition, helping businesses scale at critical stages of growth. My services will include: • Executive Search (Retained) – a high-touch, research-led approach for senior, niche and leadership hires • Contingent Search – a results-driven solution for mid-level and specialist roles • Embedded Talent Solutions – flexible support acting as part of your internal talent or HR team I am very excited for this next chapter!
Experience & Education
-
Agenus
****** ********** *******
-
**** ************
****** *********
-
****** ************
*********
-
******* ******** ********** * ******* ******* ** ********
******** ******** *************** ********* undefined
-
View Jeniece’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Recommendations received
5 people have recommended Jeniece
Join now to viewView Jeniece’s full profile
-
See who you know in common
-
Get introduced
-
Contact Jeniece directly
Other similar profiles
-
Emily Mattson
Emily Mattson
Advanced Dermatology and Cosmetic Surgery
19K followersWashington DC-Baltimore Area -
Nancy Nelson, ACIR, CIR
Nancy Nelson, ACIR, CIR
UT Southwestern Medical Center
19K followersDallas-Fort Worth Metroplex
Explore more posts
-
Alisa Sargent
Labcorp Drug Development • 2K followers
Labcorp welcomes the U.K.’s commitment to non-animal technologies through targeted investment. Together, we’re advancing regulatory science that emphasizes ethical and innovative safety testing methods. See how we’re supporting this strategy: https://lnkd.in/gYwMqd3k
5
-
Matthew Jessen
Aity8 • 5K followers
Recruiting for Specialized Roles in Biotech and Pharma Manufacturing: Biotech recruiting for specialized manufacturing roles presents unique challenges that traditional talent acquisition approaches can't handle. Pharmaceutical manufacturing jobs require candidates with particular technical expertise, regulatory knowledge, and hands-on experience, which is often challenging to find and even more complex to evaluate. This guide is designed for HR professionals, talent acquisition teams, and hiring managers… The post Recruiting for Specialized Roles in Biotech and Pharma Manufacturing appeared first on K2 Staffing. https://bit.ly/42IZ8Go
-
Nicole Scanlon
Alternative Resources… • 12K followers
Over the last six months, I’ve interviewed more than 60 marketing professionals spanning Product Manager through C‑suite, across biotech startups and large pharma, and across multiple therapeutic areas (oncology, immunology, rare disease, and more). Here’s what the market is showing: • Most top talent remains passive — not actively applying, but open to the right opportunity • The landscape is highly competitive — fewer openings mean companies must move fast and pitch well to secure marketers • Compensation continues to rise — life sciences base salaries increased by ~9% from 2023 to 2024 • In 2025, salary increase budgets are expected to be more modest (3.5–4%), but candidates with specialized skills and experience still command premium offers • Therapeutic areas like immunology and oncology are especially competitive, with demand outpacing supply • Strong cross-functional influence, launch planning experience, and digital strategy skills are among the most in-demand • Flexibility still matters — hybrid models are expected even at the senior level, especially in key hubs like Boston, NJ, and NYC If you’re hiring in branded pharma or biotech marketing, or considering a move yourself, I’d be happy to connect and share deeper insights on talent trends, compensation expectations, and hiring benchmarks.
12
-
Bill Emker
The Lotus Group LLC • 20K followers
Regeneron’s move to partner with Tessera feels like a calculated step toward building a greater genetic medicines franchise. The $150 million upfront is notable, but the more important signal is the 50/50 cost and profit share. TSRA-196 gives Regeneron a shot at a true one-time treatment for AATD, and Tessera’s gene-writing approach offers a differentiated path that avoids some of the limitations seen in viral vectors and traditional editing tools. For Regeneron, this is about owning optionality in a space where durable interventions will reshape how value is created. The next year will tell us whether the science can support the strategic ambition. Link: https://lnkd.in/eQD8A_zt
10
-
Patrick H. Stedman
Impellam Group • 4K followers
In the rapidly evolving landscape of biotechnology, finding and retaining top talent is crucial for staying competitive. Our latest case study showcases how SRG partners with a leading biotechnology company to deliver specialized talent solutions tailored to their dynamic needs. Read about how our quick turnaround satisfied an immediate need for QA shop floor resources by providing 12 top-tier candidates within just 24 hours. We can do this for you, too! From targeted talent sourcing to creating an enhanced candidate experience, SRG's comprehensive approach is driving innovation and growth in the biotech sector. Read the full case study to learn more about our successful collaboration and the impact of our talent solutions. Read More: https://lnkd.in/em2PDXcS #Biotechnology #TalentSolutions #Innovation #Growth
5
1 Comment -
Alex Halstead
Hobson Associates • 8K followers
Retention issues are critical, but they go beyond the traditional reasons such as recognition, work/life, etc. It goes to the core of employee-empowerment. People don't live and breath the company they work for anymore. They live and breath the WORK, just not the employer. Giving altruistic career ambitions, scientific ambitions, or, for lack of a better term, a bright light at the end of the tunnel to seek, is even more important given the market climate. #CGT #cdmo #hiring #retention #recruiting
6
2 Comments -
Aidan Russell
Fraser Dove International • 5K followers
Most CDMOs struggle to find Quality leaders. Why ? What’s happening in the market right now Hiring is picking up again across Cell & Gene Therapy and Biologics CDMOs. All the big name CDMOs are looking at Quality leaders and they're all fishing in the same small pond. At the same time, candidates are more cautious. Risk appetite is down. Decision cycles are longer. That combination makes mistakes expensive. Where CDMOs go wrong - Hiring on CV. Firing on behaviours. This is the pattern we see repeatedly. Deep technical CVs get prioritised Big company logos get over-weighted “They’ve done the job before” becomes the comfort blanket Then 6–12 months later, things unravel. Why? Because Quality leadership in a CDMO is different The best Quality leaders today aren’t just strong technically. They’re: Decisive under pressure Commercially aware in client-facing environments Articulate and confident with regulators and customers Executors, not consensus seekers Comfortable leading cultural and behavioural change, not just systems These traits rarely show up clearly on a CV. Add fuel to the fire Increased competition between CDMOs for the same people Restructuring across parts of the CGT space, creating quiet openness among passive leaders Limited relocatable talent and shallow networks beyond the usual names The opportunity CDMOs that get this right are shifting focus: Combination of pedigree and behaviour From job history to decision-making style From “can they run Quality?” to “can they lead Quality here?” That’s where the real differentiation now sits. Context is king. If you’re building Quality leadership in a CDMO, this is the moment to rethink how you assess and shortlist talent. #CDMO #Quality #QualityLeadership
62
6 Comments -
José Rodriguez
Novo Consulting Group LLC • 11K followers
The right talent isn’t just a hire — it’s a competitive advantage. At Novo Consulting Group LLC, we specialize in recruiting top-tier professionals within FDA-regulated industries, including: ✔ Pharmaceutical ✔ Biotechnology ✔ Medical Devices ✔ Life Sciences We focus on critical roles in: • Validation (CSV, CQV, Equipment, Process) • Quality Assurance & Regulatory Compliance • Automation & Manufacturing • Engineering & Technical Operations • Supply Chain & Procurement Our approach is consultative — not transactional. We understand compliance-driven environments, strict regulatory timelines, and the importance of placing professionals who can deliver from day one. Whether you’re scaling a project, preparing for an audit, or expanding operations — we align the right technical talent with your operational goals. If you’re hiring or exploring your next opportunity in a regulated industry, let’s connect. 📩 jrodriguez@novo-pr.com #NovoConsultingGroupLLC #Recruiting #LifeSciences #Pharma #MedicalDevices #Validation #Quality #Engineering
5
-
Vincent Zucconi
Proclinical Group • 20K followers
Big boost for U.S. pharma! 🏭🇺🇸 AbbVie is investing $195M to build a new API plant in Illinois, part of a massive $10B commitment to power next-generation therapies. Could this supercharge domestic innovation and bolster medicine security? 💊🔬💡✨ "This investment will help us maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines." – AbbVie spokesperson #Pharma #Manufacturing #Innovation #DrugDiscovery #HealthTech #LifeSciences #Biotech 💪🧬📈⚙️ Source: https://lnkd.in/eVhZhkTD
1
-
Cindy Cremona, CPC
3K followers
Bristol Myers Squibb has just unveiled a major milestone by opening their new radiopharmaceutical manufacturing facility in Indianapolis. This state-of-the-art complex is a game-changer for cancer treatment and represents a significant step forward in using radiopharmaceuticals for targeted therapies. Key highlights: - 🌟 The facility is the result of a $4.1 billion acquisition of RayzeBio in December 2023. - 📏 Spanning 77,000 square feet and costing $160 million, it focuses on producing next-generation cancer treatments using actinium-225 (Ac225). - 🧬 The plant produces isotopes and drug products, offering greater stability and targeted treatment with minimal side effects. - 💡 RayzeBio's leading candidate, RYZ101, is in Phase 3 trials for gastroenteropancreatic neuroendocrine tumors and early-stage development for small cell lung cancer. This facility not only solidifies BMS's commitment to oncology but also underscores the potential of radiopharmaceuticals in revolutionizing cancer care. With a $40 billion investment pledge in the U.S. over the next five years, it's clear that the future of cancer treatment is incredibly promising. #Oncology #Radiopharmaceuticals #HealthcareInnovation
1
-
Rachel Klaiman
GQR Global Markets • 9K followers
AstraZeneca’s experimental C5-inhibiting nanobody, gefurulimab, successfully met all primary and secondary endpoints in a 26-week Phase 3 trial for generalized myasthenia gravis—showing significant symptom improvement, strong safety and tolerability with convenient once-weekly self‑administration, positioning it as a potential $1–3 billion blockbuster and prompting upcoming regulatory discussions! https://lnkd.in/eMwT_4Rr
6
-
Andy Mitchell
LEAD3R • 12K followers
💡 The life sciences hiring market hasn’t slowed - it’s become more targeted. What we are seeing right now across pharma and biotech: 🧪 #BigPharma is prioritizing efficiency Headcount growth is selective, but roles tied to revenue protection, compliance, and launch readiness are moving. Think regulatory strategy, HEOR, medical writing, and commercial excellence. 🧫 #Biotech is operating with discipline Smaller teams, sharper mandates. Hiring is tightly linked to clinical milestones, data readouts, and investor confidence. Every role has to earn its seat. Meanwhile, some clear patterns are emerging: 👉 Hybrid profiles are winning (scientific depth + regulatory fluency) 👉 Interview processes are longer - but more intentional 👉 Candidates are doing their homework and asking better questions For job seekers: 🎯 Clarity beats volume. Know your value and articulate it crisply. 🎯 Relationships matter more than ever - warm intros open doors faster than applications. For hiring leaders: ⏱️ When the right person shows up, don’t over-optimize. The best candidates aren’t waiting around. The market isn’t easy - but it is full of opportunity if you know how to read the signals. #biotechjobs #pharmajobs #hiring #talentmarket
32
4 Comments -
Nick Shearing
Evolve Scientific an NES… • 13K followers
🌐 Key CRO Industry Trends 2025 shared by Gary Ellsworth, VP & Head of North America Alliance Management, IQVIA in Contract Pharma article: 🚀 EBPs on the rise – 63% of trial starts driven by emerging biopharma, needing CRO support from design ➝ commercialization. 🏢 Mid-sized pharma - Filling resource gaps with tailored CRO partnerships. 🇨🇳 China’s growing role - 30% of trial starts; strong licensing & partnership opportunities. ⚡ Efficiency focus - Reducing “white space” between phases with AI, decentralized trials, & real-world evidence. 🧬 Therapeutic priorities - Oncology, neurology, immunology, & cardiovascular dominate; obesity R&D booming 📈. 💻 Decentralized trials - Expanding patient access while ensuring quality & empathy. 📊 Data complexity - Tripling over the past decade, driving demand for connected, standards-based strategies. 🤝 The future of drug development will depend on strategic sponsor–CRO partnerships to navigate complexity and deliver innovative therapies faster. 🔗 Full Article: https://lnkd.in/gdF2S6nM #ClinicalTrials #CRO #Biopharma #DrugDevelopment #Outsourcing #IQVIA
11
1 Comment -
Hugo Orchard
SoftPace Pharma • 7K followers
From a recruiter’s perspective in the US life sciences market, 2026 feels different - in a good way.👍 Biotech and pharma companies are more focused, more intentional, and clearer about what talent actually drives value. That means fewer “nice-to-have” roles and more mission-critical hires. We’re seeing strong activity in: • Clinical development leadership • Regulatory affairs • Manufacturing scale-up • AI/data-driven biology If you’re building teams or considering your next career move in biotech or pharma, this is a year to be proactive - not reactive.😉 #Biotech #Pharma #LifeSciencesRecruiter #HiringTrends #2026
22
-
Kimberly Laipple
Scientific Search • 30K followers
Large firms bring scale. Boutique firms bring signal. In life sciences recruiting, nuance matters: • Regulatory pathway experience • Modality expertise • Phase-specific leadership • Scientific credibility We don’t just scan resumes, we understand pipelines, platforms, and pressure points. In highly specialized markets, precision beats volume. #precision #lifesciences
8
3 Comments -
Sam Gibbons
R&D Partners • 15K followers
👨🔬💬 𝐂𝐞𝐥𝐥 & 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐢𝐭𝐲: 𝟐𝐧𝐝 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟓 👩🔬💬 🧬 Solid Biosciences received FDA Rare Pediatric Disease designation for SGT-212, its investigational gene therapy for Friedreich’s ataxia (FA). SGT-212 uses a dual direct intradentate nucleus (IDN) and intravenous (IV) infusion approach to deliver the full-length frataxin gene, aiming to restore therapeutic protein levels and address neurological, cardiac, and systemic symptoms of FA. 🦠 NorthX Biologics and Mendus AB announced achieving GMP certification for manufacturing vididencel, Mendus’ lead cell therapy for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). This milestone follows a strategic alliance formed in 2023 to establish scalable, GMP-compliant cell therapy production in Sweden. The collaboration enabled tech transfer and clinical-grade batch production, supporting Mendus’ late-stage trials and commercialization plans. 🧬 Regeneron partnered with Tessera Therapeutics to co-develop TSRA-196, an in vivo gene writing therapy for alpha-1 antitrypsin deficiency (AATD). Regeneron will invest $150M in equity and upfront payments for 50% global rights, with Tessera eligible for $125M in milestones, bringing the deal value to $275M. If successful, TSRA-196 could become the first disease-modifying therapy for AATD, a market projected to grow from $1.2B in 2023 to $3.48B by 2031. 🦠 Longeveron reported Phase 2 CLEAR-MIND trial results showing its stem cell therapy, laromestrocel, reduced neuroinflammation in patients with mild Alzheimer’s disease compared to placebo. The therapy demonstrated durable improvements across 13 of 14 brain regions, notably the hippocampus, using diffusion tensor imaging and free water analysis at week 39. 🧬 Ensoma announced dosing the first patient in its Phase 1/2 trial of EN-374, an in vivo hematopoietic stem cell (HSC)-directed gene insertion therapy for X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder causing severe infections. EN-374 uses virus-like particles to deliver a CYBB transgene to HSCs, aiming to restore NADPH oxidase function and immune defense through a one-time treatment. The trial will assess safety, tolerability, and preliminary efficacy, with adult cohorts followed by pediatric enrollment. 🦠 NextCell Pharma AB partnered with OptiCell Solutions AB to enhance cell handling, freezing, storage, and transport for research and development purposes. Under the agreement, OptiCell will manage donor and customer relations, including apheresis operations at its Huddinge clinic, while NextCell oversees cell processing and logistics. Revenue from these services will support development of ProTrans™, NextCell’s lead candidate for type 1 diabetes. 🛎 My aim is to be the messenger when it comes to your CGT news. Follow #mCGT to stay updated! #celltherapy #genetherapy #ATMP #advancedtherapy
67
-
Elizabeth Pettit
Pettit Pharma & Device Search • 12K followers
YAY! 3rd year in a row! At PPD Search, we know that candidate experience relates to finding, hiring and retaining talent. The on-boarding process takes place immediately following us briefing candidates on opportunities. The statistics around poor candidate experience would make you cringe. Did you know that 56% of candidates would discourage others from applying due to a bad recruiting experience? Candidates have higher expectations than ever, and a slow or frustrating hiring process can send them straight to a competitor and you may even lose them as customers. We know that even if they take the job, they do not forget about the hiring process and are left wondering "is this the right place for me?", it only takes a few other niggly negative things to happen in the first 90 days to reinforce in their mind that the hiring experience aligns with their on-boarding, which if not strong, the new employee starts looking for another job, in fact 84% of the Australian workforce has stated that they are either looking for a new role or open to opportunities that might be presented to them. #onboarding #culture #candidateexperience
34
2 Comments -
Aimee Joy
Labcorp • 4K followers
Colon cancer is on the rise, especially for people under 50. Learn how Labcorp sought to improve employee health and lower costs with its employer-sponsored colorectal cancer screening program—and how Labcorp can help you implement a similar program to meet the needs of your employee or member population. Learn more: https://lnkd.in/e9kCNiwv
6
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content